logo
Plus   Neg
Share

Short-Term Investor Stock GLOB Gains 64.3%

The stock, Globant (GLOB), featured on our 'Short-Term Investor' on November 16, 2018, at an opening price of $51.23. On April 24, 2019, the stock touched an intra-day high of $84.19, representing a gain of 64.3%. On August 1, 2019, the stock touched a new 52-week high of $112.33, and closed Friday's trade at $93.45.

Why we published this stock?

Globant reported better-than-expected Q3 results and issued upbeat 2018 guidance.

Q4, FY Outlook

The company projected Q4 revenues in the range of $138 million - $140 million, implying 20.4% year-over-year growth at the midpoint of the range. Q4 Non-IFRS adjusted EPS was estimated to be in the range of $0.45-$0.49. Wall Street analysts then expected earnings of $0.46 per share on revenue of $136.3 million.

For fiscal 2018, the company expected revenues in the range of $520 million - $522 million, implying 26.0% year-over-year revenues growth at the midpoint of the range; and non-IFRS adjusted EPS in the range of $1.69-$1.73. Analysts then estimated earnings of $1.68 per share and revenue of $515.13 million for 2018.

Q3 Results

The company's Q3 net income was $15.5 million or $0.42 per share compared to $7.9 million or $0.22 per share last year.

Adjusted net income was $16.8 million or $0.46 per share, higher than the prior year's adjusted income of $13.6 million or $0.37 per share.

Revenues for the quarter increased to $134.6 million from $109.7 million generated in the previous year.

Analysts polled by Thomson Reuters expected earnings of $0.44 per share on revenue of $132.6 million for the quarter. Analysts' estimate typically exclude certain special items.

"Third quarter 2018 was another robust quarter for Globant. Our revenues reached a new quarterly record of $134.6 million, with an implied 22.7% year-over-year growth. This solid growth was mainly driven by top 10 accounts, which delivered revenues growth of 37.8% over third quarter of 2017 and 7.9% sequentially," said Martín Migoya, Globant's CEO and co-founder.

Free Sign Up
Free Sign Up

Short-Term Investor Top Perfomers
Pub. DateCompany% Gain
01/10/2018 TNDM + 696.14
05/08/2018 TREX + 211.39
05/17/2016 MIME + 207.12
01/07/2016 QUAD + 198.90
05/24/2016 EXEL + 185.08
08/08/2019 ACMR + 184.92
01/30/2015 CORT + 161.51
01/19/2017 TAL + 149.84
08/20/2015 MSG + 141.43
01/09/2017 EXAS + 140.34
Complete Performance
Under the Radar Top Perfomers
Pub. DateCompany% Gain
04/27/2020 MDGS + 108.50
02/20/2013 IKNX + 99.41
08/13/2014 INGN + 98.42
11/11/2014 CYAN + 89.14
02/22/2019 BOOM + 87.02
12/11/2014 INTL + 86.33
03/07/2019 FLY + 81.83
10/23/2014 OFLX + 81.26
08/14/2014 AMOT + 79.00
02/07/2018 MHH + 78.84
09/11/2014 MSON + 78.44
Complete Performance
Emerging Biostocks Top Perfomers
Pub. DateCompany% Gain
04/19/2017 MRTX + 1576
07/17/2018 AMRN + 737
04/05/2017 MYOK + 734
10/03/2019 CNST + 552
02/11/2016 TBRA + 542
11/25/2017 CBIO + 464
09/03/2019 APLT + 437
11/03/2019 THOR + 362
09/21/2018 CCXI + 339
11/23/2017 ARGX + 302
02/05/2018 VKTX + 295
01/18/2018 ADVM + 218
06/06/2018 CSBR + 216
03/26/2020 MRNA + 216
04/06/2020 TBIO + 184
03/03/2020 OVID + 181
04/08/2019 SOLY + 170
09/10/2018 NTEC + 140
06/20/2019 ZYXI + 106
Complete Performance
Free Sign Up